AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19461031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 17805088 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF/CHO
Number of subjects: 12
Study 17805088 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA/CHO
Number of subjects: 12
Study 17805088 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF/PLA
Number of subjects: 12
Study 15741486 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (N=20)
Number of subjects: 52
Study 15741486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 52
Study 12236459 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, individualized alcohol abuse prevention program
Number of subjects: 155
Study 12236459 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 155
Study 9823973 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARTWEL 60 Gy in 16 days
Number of subjects: 0
Study 9823973 — intervention group
Group type: COMPARATOR
Intervention: CHARTWEL 54 Gy in 16 days
Number of subjects: 0
Study 7865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-headed toothbrush
Number of subjects: 30
Study 7865417 — intervention group
Group type: COMPARATOR
Intervention: Single-headed toothbrush
Number of subjects: 30
Study 2919762 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexital
Number of subjects: 64
Study 2919762 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 64
Study 2919762 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 64
Study 31894603 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf Expander appliance
Number of subjects: 101
Study 31894603 — intervention group
Group type: COMPARATOR
Intervention: Hyrax expansion screw
Number of subjects: 101
Study 31894603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 31695332 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 liquid supplementation (100 mg/day for 3 months)
Number of subjects: 60
Study 31695332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29246188 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg orally three times a day for 100 days
Number of subjects: 160
Study 29246188 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally three times a day for 100 days
Number of subjects: 160
Study 25342855 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 77
Study 25342855 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 77
Study 25029835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizhen treatment, once a week for 2 weeks (1 treatment course)
Number of subjects: 116
Study 25029835 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture massage instrument, 20 minutes once a day for 2 weeks
Number of subjects: 116
Study 25029835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizhen treatment
Number of subjects: 116
Study 25029835 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture massage instrument
Number of subjects: 116
Study 22939637 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF)
Number of subjects: 100
Study 19527383 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 320
Study 19527383 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with pill count
Number of subjects: 320
Study 19527383 — intervention group
Group type: COMPARATOR
Intervention: Pill count alone
Number of subjects: 320
Study 17311735 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner notification by practice nurses
Number of subjects: 19773
Study 17311735 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based postal chlamydia screening
Number of subjects: 19773
Study 17311735 — intervention group
Group type: COMPARATOR
Intervention: Screening men and women annually
Number of subjects: 19773
Study 17311735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic acid amplification tests
Number of subjects: 19773
Study 17311735 — intervention group
Group type: COMPARATOR
Intervention: Screening
Number of subjects: 19773
Study 17311735 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-sampling
Number of subjects: 19773
Study 15337655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 370
Study 15337655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 15337655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 370
Study 14575396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 14575396 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 10599961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcon/HMS system
Number of subjects: 114
Study 10599961 — intervention group
Group type: COMPARATOR
Intervention: ACT group
Number of subjects: 114
Study 7842421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening in women aged 40-49 years
Number of subjects: 0
Study 7842421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality analyses eliminating advanced cases detected by physical examination
Number of subjects: 0
Study 1903723 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 50
Study 1903723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6264825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cl2MDP (1600 mg daily for 12 weeks)
Number of subjects: 14
Study 6264825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 14
Study 31477359 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 48
Study 31477359 — intervention group
Group type: COMPARATOR
Intervention: Conventional Active Drug Mixture (CADM)
Number of subjects: 48
Study 29969808 — intervention group
Group type: EXPERIMENTAL
Intervention: EPLBD alone
Number of subjects: 200
Study 29969808 — intervention group
Group type: COMPARATOR
Intervention: EPLBD with EST
Number of subjects: 200
Study 29030802 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretta treatment
Number of subjects: 20
Study 29030802 — intervention group
Group type: COMPARATOR
Intervention: Control group (PPIs)
Number of subjects: 20
Study 24913739 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (FM) therapy
Number of subjects: 45
Study 24913739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-plate appliance/facemask (DPA-FM) therapy
Number of subjects: 45
Study 24913739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 24360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led group
Number of subjects: 0
Study 24360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-led group
Number of subjects: 0
Study 24360924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22672576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention (STEP) including one group meeting, log-monitored pedometer-use, and six e-mail messages from OHC
Number of subjects: 241
Study 22672576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention (STEP)
Number of subjects: 241
Study 22672576 — intervention group
Group type: COMPARATOR
Intervention: Control group (COMP)
Number of subjects: 241
Study 19392952 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial 12-month fall prevention program
Number of subjects: 591
Study 17884371 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 500
Study 17884371 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 500
Study 14687046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 300 mg twice daily
Number of subjects: 46
Study 14687046 — intervention group
Group type: COMPARATOR
Intervention: S-adenosyl-l-methionine 500 mg twice daily
Number of subjects: 46
Study 12452381 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on the Zusanli (St 36) points
Number of subjects: 15
Study 12452381 — intervention group
Group type: COMPARATOR
Intervention: Intravenous atropine before electroacupuncture
Number of subjects: 15
Study 9408704 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) releasing 20 micrograms ethinyl estradiol and 1 mg of norethindrone acetate daily over two successive cycles with three different insertion regimens
Number of subjects: 159
Study 9408704 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR)
Number of subjects: 159
Study 7685429 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy with Urolase right angle firing neodymium:YAG laser fiber
Number of subjects: 25
Study 7685429 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral electroresection of the prostate
Number of subjects: 25
Study 7685429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study 3032224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 60
Study 3032224 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisone
Number of subjects: 60
Study 31210085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal breathing sounds analysis using a support vector machine (SVM) classifier
Number of subjects: 122
Study 31210085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal breathing sounds analysis with anthropometric parameters and a voting procedure
Number of subjects: 122
Study 27396240 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in G1 (120≤eGFR)
Number of subjects: 1407
Study 27396240 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in G2 (90≤eGFR<120)
Number of subjects: 1407
Study 27396240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decliners (annual eGFR decline rate≥3ml/min/1.73m2)
Number of subjects: 1407
Study 27396240 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR<60ml/min/1.73m2 at follow-up
Number of subjects: 1407
Study 25202842 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program targeting coaches' knowledge and management of eating disorders, nutrition, and weight regulation.
Number of subjects: 76
Study 23383975 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto (320 mg gelcap daily for 24 weeks, then 2 gelcaps daily for 24 weeks, then 3 gelcaps daily for 24 weeks)
Number of subjects: 306
Study 23383975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo gelcaps for the same durations)
Number of subjects: 306
Study 23383975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (saw palmetto and placebo)
Number of subjects: 306
Study 22608494 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin E 800 mg, C 500 mg, zinc 40 mg) for 6 months
Number of subjects: 0
Study 22608494 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (pegylated interferon combined with ribavirin)
Number of subjects: 0
Study 22608494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 19095492 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with traditional swallowing training
Number of subjects: 26
Study 19095492 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation plus traditional swallowing training
Number of subjects: 26
Study 19095492 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES combined with traditional swallowing training
Number of subjects: 26
Study 17150287 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPPV) during the third trimester or at delivery
Number of subjects: 0
Study 17150287 — intervention group
Group type: COMPARATOR
Intervention: Vaccination at 7 months post delivery
Number of subjects: 0
Study 15373174 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon 320 mg/day
Number of subjects: 124
Study 15373174 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 124
Study 11255445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment (2 to 12 mg/d) for 26 weeks after 26 weeks of placebo treatment
Number of subjects: 187
Study 9663162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (training, feedback, and prompts)
Number of subjects: 54
Study 9663162 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 54
Study 7944817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm antegrade cardioplegia
Number of subjects: 72
Study 7944817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid antegrade cardioplegia
Number of subjects: 72
Study 7944817 — intervention group
Group type: COMPARATOR
Intervention: Cold antegrade cardioplegia
Number of subjects: 72
Study 7944817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia
Number of subjects: 72
Study 7944817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid retrograde cardioplegia
Number of subjects: 72
Study 7944817 — intervention group
Group type: COMPARATOR
Intervention: Cold retrograde cardioplegia
Number of subjects: 72
Study 3555386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine hydrochloride treatment
Number of subjects: 0
Study 3555386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1790567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1 mg/kg)
Number of subjects: 25
Study 1790567 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 25
Study 405029 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol administered rectally
Number of subjects: 0
Study 31562522 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (1-standard deviation increase, equivalent to 3.6 years)
Number of subjects: 0
Study 31562522 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (after adjusting for cognition)
Number of subjects: 0
Study 31562522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition (1-standard deviation increase)
Number of subjects: 0
Study 31562522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition (after adjusting for education)
Number of subjects: 0
Study 28645052 — intervention group
Group type: EXPERIMENTAL
Intervention: Active filtration (filter in)
Number of subjects: 35
Study 28645052 — intervention group
Group type: COMPARATOR
Intervention: Sham-mode filtration (filter out)
Number of subjects: 35
Study 25380413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 16
Study 25380413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 16
Study 25380413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23865673 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary protein:creatinine ratio (PrCr) measured using pyrocatechol violet assay
Number of subjects: 160
Study 23865673 — intervention group
Group type: EXPERIMENTAL
Intervention: Last urine sample before delivery
Number of subjects: 160
Study 23865673 — intervention group
Group type: EXPERIMENTAL
Intervention: Known normal pregnancy outcome
Number of subjects: 160
Study 23865673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrogallol red assay
Number of subjects: 160
Study 21740236 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated (LA) group using LED/laser energy
Number of subjects: 30
Study 21740236 — intervention group
Group type: COMPARATOR
Intervention: Non-activated (NA) group
Number of subjects: 30
Study 21740236 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated (LA) group
Number of subjects: 30
Study 21740236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 19881236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 36
Study 19881236 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 36
Study 16442954 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) 50 or 100 mug/kg
Number of subjects: 0
Study 16442954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14711909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 1186
Study 14711909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin followed by epinephrine
Number of subjects: 1186
Study 14711909 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 1186
Study 11377597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine
Number of subjects: 701
Study 11377597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 9471918 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with osteoporosis (n=50)
Number of subjects: 80
Study 9471918 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 80
Study 9471918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 8098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70%)
Number of subjects: 40
Study 8098692 — intervention group
Group type: COMPARATOR
Intervention: O2/air
Number of subjects: 40
Study 2956923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 175
Study 2956923 — intervention group
Group type: COMPARATOR
Intervention: General, balanced anaesthesia
Number of subjects: 175
Study 31957972 — intervention group
Group type: EXPERIMENTAL
Intervention: HPR switch group (ticagrelor)
Number of subjects: 1353
Study 31957972 — intervention group
Group type: COMPARATOR
Intervention: HPR nonswitch group (clopidogrel)
Number of subjects: 1353
Study 31957972 — intervention group
Group type: COMPARATOR
Intervention: non-HPR group
Number of subjects: 1353
Study 31957972 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1353
Study 30696326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks of supervised training twice weekly including interval-based aerobic exercise and resistance training)
Number of subjects: 50
Study 30696326 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 50
Study 27933731 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence-associated dermatitis (IAD) category 2
Number of subjects: 381
Study 27933731 — intervention group
Group type: EXPERIMENTAL
Intervention: Less mobility
Number of subjects: 381
Study 27933731 — intervention group
Group type: EXPERIMENTAL
Intervention: More friction and shear issues
Number of subjects: 381
Study 27933731 — intervention group
Group type: EXPERIMENTAL
Intervention: More erythema due to incontinence
Number of subjects: 381
Study 25530107 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium concentration (5 mEq/L below serum sodium)
Number of subjects: 16
Study 25530107 — intervention group
Group type: COMPARATOR
Intervention: High dialysate sodium concentration (5 mEq/L above serum sodium)
Number of subjects: 16
Study 23566075 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 900
Study 23566075 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 900
Study 23566075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 900
Study 23566075 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 900
Study 20870757 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 60
Study 20870757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18492531 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS063DP cream (n = 72)
Number of subjects: 142
Study 18492531 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (n = 70)
Number of subjects: 142
Study 16812973 — intervention group
Group type: COMPARATOR
Intervention: Efalizumab
Number of subjects: 4165
Study 16812973 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (1 mg/kg)
Number of subjects: 4165
Study 16812973 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (2 x 25 mg)
Number of subjects: 4165
Study 16812973 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg)
Number of subjects: 4165
Study 16812973 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatment
Number of subjects: 4165
Study 11880085 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasectomy plus irrigation of each vas deferens with sterile water
Number of subjects: 200
Study 11880085 — intervention group
Group type: COMPARATOR
Intervention: Standard vasectomy
Number of subjects: 200
Study 10717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2%, 0.4%, 0.6%)
Number of subjects: 14
Study 10717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 14
Study 10717960 — intervention group
Group type: COMPARATOR
Intervention: Placebo-oxygen
Number of subjects: 14
Study 10717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 14
Study 10717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14
Study 7779574 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc gluconate twice (the evening before and 30 min before the test)
Number of subjects: 7
Study 7779574 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 7
Study 1970070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement (250 ml, 20 g protein, 254 kcal) for a mean of 32 days
Number of subjects: 59
Study 471861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 prophylaxis during operation
Number of subjects: 100
Study 471861 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group with drospirenon
Number of subjects: 20